Dose Response and Atypical Antipsychotics in Schizophrenia
作者:
Bruce J Kinon,
Jonna Ahl,
Virginia L Stauffer,
Angela L Hill,
Peter F Buckley,
期刊:
CNS Drugs
(ADIS Available online 2004)
卷期:
Volume 18,
issue 9
页码: 597-616
ISSN:1172-7047
年代: 2004
出版商: ADIS
关键词: Antipsychotics, therapeutic use;Haloperidol decanoate, therapeutic use;Sertindole, therapeutic use;Risperidone, therapeutic use;Quetiapine, therapeutic use;Aripiprazole, therapeutic use;Haloperidol, therapeutic use;Fluphenazine, therapeutic use;Clozapine,
数据来源: ADIS
摘要:
Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose related. The overlapping nature of these dose-response profiles limits the use of these agents. Atypical antipsychotics provide greater relief across the comorbid symptom domains of schizophrenia, but dose-response studies and clinical experience have revealed that some of these drugs also have dose limitations. This article reviews the dose-response relationships of the atypical antipsychotics as presented predominantly in pivotal, randomised studies (double-blind and otherwise).Limited data indicate that clozapine shows dose-related efficacy up to 600 mg/day in patients with treatment-resistant schizophrenia. However, higher dosages of clozapine may be associated with the risk of seizures. Risperidone demonstrates dose-related adverse events that compromise efficacy. The dose-response relationships for ziprasidone, quetiapine and aripiprazole are less well established. The efficacy of olanzapine appears to be dose related within the recommended dosage range of 10–20 mg/day, but clinical trials that have explored higher dosages suggest improved efficacy. Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events.Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics.
点击下载:
PDF
(268KB)
返 回